目的:分析促红细胞生成素减少贫血患者输血量的临床效果。方法:随机选取我院2013年1月到12月收治的贫血患者67例作为观察组,给予促红细胞生成素治疗,选取同期采取输血的贫血患者67例作为对照组,分析其应用效果。结果:两组患者治疗后Hb明显上升,与治疗前对比(P<0.05),组间对比(P>0.05)。观察组皮下注射Hb上升速度高于静脉注射(P<0.05)。治疗期间无不良反应。结论:在治疗贫血患者中采用促红细胞生成素,可促进造血,并快速纠正贫血,而在输血时,需考虑患者耐受程度,根据贫血严重性进行输血。 Objective: To analyze the clinical effect of erythropoietin in reducing blood transfusion in patients with anemia. Methods: A total of 67 anemia patients admitted from January 2013 to December 2013 in our hospital were selected as the observation group. Erythropoietin was given to the patients. A total of 67 anemia patients receiving blood transfusions during the same period were selected as the control group, and their effects were analyzed. Results: After treatment, the Hb level increased significantly in both groups (P <0.05), compared with before treatment (P> 0.05). Hb in subcutaneous injection in the observation group was higher than that in the intravenous injection (P <0.05). No adverse reactions during treatment. CONCLUSIONS: The use of erythropoietin in the treatment of anemia can promote hematopoiesis and rapidly correct anemia. However, in transfusion, the degree of patient tolerance needs to be considered, and blood transfusion should be based on the severity of anemia.